Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00803543 · ClinicalTrials.gov registry record · NA
Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding
A NA study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 103
- Enrollment target
NCT00803543 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 103 participants.
The verdict
NCT00803543, a NA study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 103 participants
- Enrollment target
Study Summary
The purpose of the study is to determine how common herpes is among persons with HIV who do not know they have it and if valacyclovir reduces outbreaks of herpes, the amount of HIV in the blood, and the amount of HSV in bodily secretions.
Interventions
- DRUG Placebo
- DRUG Valacyclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2009-01 |
| Est. Completion | 2014-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00803543
The ClinicalTrials.gov registry entry for NCT00803543 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00803543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00803543 about?
NCT00803543 is a clinical study titled "Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding". The purpose of the study is to determine how common herpes is among persons with HIV who do not know they have it and if valacyclovir reduces outbreaks of herpes, the amount of HIV in the blood, and the amount of HSV in bodily secretions.
What is the current status of trial NCT00803543?
This trial is currently completed. It is a NA study. The enrollment target is 103 participants. The study started on 2009-01. Estimated completion is 2014-04.
What interventions are being tested in trial NCT00803543?
The interventions under investigation include: Placebo (DRUG), Valacyclovir (DRUG).
Who is sponsoring clinical trial NCT00803543?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.